|
Nomdedéu JF, Hoyos M, Carricondo M, Bussaglia E, Estivill C, Esteve J, Tormo M, Duarte R, Salamero O, de Llano MP, García A, Bargay J, Heras I, Martí-Tutusaus JM, Llorente A, Ribera JM, Gallardo D, Aventin A, Brunet S, Sierra J; CETLAM Group.. Bone marrow WT1 levels at diagnosis, post-induction and post-intensification in adult de novo AML. Leukemia. 2013 Nov;27(11):2157-64. doi: 10.1038/leu.2013.111. PubMed PMID: 23584566.
AÑO: 2013; IF: 9.379
|
23584566
|
Caballero-Velázquez T, López-Corral L, Encinas C, Castilla-Llorente C, Martino R, Rosiñol L, Sampol A, Caballero D, Serrano D, Heras I, San Miguel J, Pérez-Simón JA. Phase II clinical trial for the evaluation of bortezomib within the reduced intensity conditioning regimen (RIC) and post-allogeneic transplantation for high-risk myeloma patients. Br J Haematol. 2013 Aug;162(4):474-82. doi: 10.1111/bjh.12410. PubMed PMID: 23772672.
AÑO: 2013; IF: 4.959
|
|
Hernández-Fernández A, Oñate-Sánchez RE, Cabrerizo-Merino MC, de Arriba-de la-Fuente F, Heras-Fernando I, Vicente-García V. Influence of oral health on mucositis in patients undergoing hematopoietic progenitor cell transplantation (HPCT). Med Oral Patol Oral Cir Bucal. 2012 Jan 1;17(1):e94-e101. PubMed PMID: 22157660; PubMed Central PMCID: PMC3448185.
AÑO: 2012; IF: 1.13
|
|
Llorente A, Perez-Valero I, García E, Heras I, Fraile V, García P, López J, Salavert M, Bobillo F. Mortality risk factors in patients with zygomycosis: a retrospective and multicentre study of 25 cases. Enferm Infecc Microbiol Clin. 2011 Apr;29(4):263-8. doi: 10.1016/j.eimc.2010.09.008. Epub 2011 Feb 16. PubMed PMID: 21330008.
AÑO: 2011; IF: 1.491
|
|
Jerez A, Osma Mdel M, Castilla-Llorente C, Bernal A, Palacios S, Heras I, Ortuño FJ. Transient bone marrow lymphoproliferation after umbilical cord blood transplantation: exacerbated reconstitution of B-cell ontogeny in adults. Am J Hematol. 2011 Jun;86(6):518-20. doi: 10.1002/ajh.22013. PubMed PMID: 21594890.
AÑO: 2011; IF: 4.671
|